A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).

Chandrayee GhoshSuresh KumarYevgeniya KushchayevaKelli GaskinsMyriem BoufraqechDarmood WeiSudheer Kumar GaraLisa ZhangYa-Qin ZhangMin ShenSanjit MukherjeeElectron Kebebew

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Combination treatment with ponatinib and PLX4720 exhibited significant synergistic anticancer activity in preclinical models of BRAF V600E thyroid cancer, in addition to overcoming PLX4720 resistance. Our results suggest this combination should be tested in clinical trials.

Keyphrases

clinical trial
wild type
cancer therapy
metastatic colorectal cancer
chronic myeloid leukemia
randomized controlled trial
phase ii
bone marrow
study protocol
phase iii